Informative Resources

Take a look at the latest on Palatin across our media publications, posters, and presentations.

Bremelanotide Provides Meaningful Treatment Benefits for Premenopausal Women With Hypoactive Sexual Desire Disorder


Bremelanotide, a melanocortin receptor agonist and an analog of the endogenous neuropeptide α-melanocortin stimulating hormone, has been approved in the US for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The RECONNECT studies demonstrated that subcutaneous self-administration of bremelanotide significantly improved sexual desire and decreased personal distress in premenopausal women with HSDD.

Conversations With Women About Female Sexual Dysfunction (FSD) and Treatment With Bremelanotide


Female sexual dysfunctions (FSD) include a range of distressing, multifactorial conditions, such as dysfunctions of sexual interest/desire, sexual arousal, a delay in or absence of orgasm, and sexual pain. The most common sexual concern expressed by women is diminished or lack of desire for sexual activity, which may be diagnosed as hypoactive sexual desire disorder (HSDD), if the lack of desire causes distress. Bremelanotide (BMT), a novel cyclic 7-amino acid melanocortin-receptor agonist with the potential to modulate neural pathways involved in sexual response, is being developed to treat FSD.

Probing the Role of the MC1 Receptor Agonists in Diverse Immunological Diseases


Carl Spana, Andrew W. Taylor, David G. Yee, Marie Mahklina, Wei Yang, John Dodd, Presented at TIDES: Oligonucleotide and Peptide Therapeutics 2018

Safety and Efficacy of Bremelanotide for HSDD in Women: RECONNECT Study Open-Label Extension Phase Results


Results from the Core Study Phase have been reported previously. This presentation includes long-term safety and efficacy results from the RECONNECT Open-Label Extension (OLE) Study Phase.

The Neurobiology and Efficacy of Bremelanotide in HSDD


Describes how bremelanotide, an analog of the naturally occurring peptide α-melanocyte-stimulating hormone (α-MSH), acts on the physiological and neurobiological components of female sexual function to improve sexual arousal and desire in women with HSDD.

Bremelanotide for Hypoactive Sexual Desire Disorder: Age and Weight Subgroup Efficacy Analyses From the RECONNECT Studies


Analyses of the co-primary and key secondary endpoints were performed as exploratory analyses for the age and weight subgroups of the RECONNECT studies to assess the consistency of BMT’s effect.

Exit Survey of Women With Hypoactive Sexual Desire Disorder Treated With Bremelanotide in the RECONNECT Studies Demonstrated Meaningful Treatment Benefits


The objective of this survey was to understand the impact of HSDD in premenopausal women and to provide a deeper understanding of the effect and impact/meaningfulness of BMT beyond clinical trial results.

Development of a Patient-Centric Exit Study to Contextualize and Assess Meaningfulness of a Potential Treatment for Hypoactive Sexual Desire Disorder (HSDD)


Female sexual dysfunctions (FSD) include a group of conditions characterized by physiological, psychological, and social components. The most common sexual concern expressed by women with FSD is diminished or lack of desire for sexual activity. When accompanied by distress, this may be diagnosed as hypoactive sexual desire disorder (HSDD). Bremelanotide (BMT; PT-141) is an investigational drug being developed as a treatment for HSDD in premenopausal women.

Efficacy of the Investigational Drug Bremelanotide in the RECONNECT Studies


To evaluate the safety and efficacy of BMT 1.75 mg self-administered, as-desired, for the treatment of HSDD.

Changes in Sexual Functioning in the Bremelanotide RECONNECT Study


Two Phase 3 studies assessed the efficacy and safety of a 1.75-mg dose of BMT administered on an as-desired basis for the treatment of HSDD. Here we present the secondary efficacy results.

Scroll to Top